
Bio Design Lab
Innovative biopharmaceuticals leveraging synthetic biology and advanced genetic designs for cell and gene therapies.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | KRW7.0b | Series B | |
Total Funding | 000k |
Bio Design Lab is a pioneering company in the biotechnology and bioengineering sectors, specializing in the creation and development of highly potent biopharmaceuticals. Utilizing synthetic biology and systems-level genetic and genomic designs, the company focuses on advancing retroviral and lentiviral vector platforms, which are essential technologies for cell and gene therapies. Bio Design Lab collaborates with Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs) interested in licensing its viral vector technologies. The company also seeks strategic partnerships with firms that have clinical expertise and a keen interest in developing innovative therapeutics using its cutting-edge viral vector platforms. Bio Design Lab's approach involves optimizing and engineering individual biomolecular components through advanced genetic techniques, assembling these components with selected features, and employing computational genetic and genomic models to design optimized connections. This method aims to overcome the limitations of conventional biopharmaceutical development, which often results in unexpected serious side effects. By applying systems-level genetic and genomic design strategies, Bio Design Lab aims to create more effective biopharmaceuticals.
Keywords: biopharmaceuticals, synthetic biology, genetic design, viral vectors, cell therapy, gene therapy, CDMOs, CMOs, strategic partnerships, computational models.